<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480271</url>
  </required_header>
  <id_info>
    <org_study_id>114450</org_study_id>
    <nct_id>NCT01480271</nct_id>
  </id_info>
  <brief_title>An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled First Time Into Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intranasal Dosing With GSK2245035, a TLR7 Agonist, in Healthy Volunteers and Allergic Rhinitics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2245035 is a highly selective Toll-like Receptor 7(TLR7) agonist capable of preferentially&#xD;
      inducing the production of interferon alpha (IFNα) versus tumor necrosis factor alpha (TNFα).&#xD;
      The aim of this FTIH study is to collect tolerability, pharmacokinetic (PK) and&#xD;
      pharmacodynamic (PD) information to enable the identification of appropriate safe doses of&#xD;
      intranasal (i.n) GSK2245035, associated with up-regulation of TLR7-mediated genes in the&#xD;
      nasal milieu, for use in subsequent clinical drug development studies. There will be two&#xD;
      parts to the study: Healthy Volunteers will be dosed in escalating single doses in Part 1,&#xD;
      followed by Allergic Rhinitis (AR) subjects dosed similarly in Part 2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a First Time in Human (FTIH) study to investigate the safety, tolerability,&#xD;
      pharmacokinetics (PK) and pharmacodynamics (PD) of single, escalating doses of intranasal&#xD;
      (i.n.) GSK2245035 in healthy male volunteers (HVT) and male subjects with allergic rhinitis&#xD;
      (AR). The safety and tolerability of single i.n. GSK2245035 dosing will be assessed and&#xD;
      established in HVT before the initiation of evaluation in AR.&#xD;
&#xD;
      GSK2245035 is a highly selective Toll-like Receptor 7 (TLR7) agonist capable of&#xD;
      preferentially inducing the production of IFNα rather than TNFα. Activation of TLR7 is known&#xD;
      to result in upregulation of co-stimulatory signals on antigen-presenting cells and in&#xD;
      generation of pro-inflammatory mediators that can shift bystander immune responses towards a&#xD;
      Helper T-cell Type 1/ Regulatory T cell (Th1/Treg) phenotype and therefore reduce the&#xD;
      magnitude of Helper T-cell Type 2 (Th2) reactivity. In this context, it is proposed that i.n.&#xD;
      GSK2245035 administration may alter the airways immune environment in a way that results in&#xD;
      long-lasting control of AR symptoms and potentially disease remission through persistent&#xD;
      modification of the underlying aberrant Th2 responsiveness to aeroallergens.&#xD;
&#xD;
      The aim of this study is to collect tolerability, PK and PD information to enable the&#xD;
      identification of appropriate safe doses of i.n. GSK2245035, associated with up-regulation of&#xD;
      TLR7-mediated genes in the nasal milieu, for use in subsequent clinical drug development&#xD;
      studies. The study will be divided in to two parts. Part 1, involving only healthy&#xD;
      volunteers, will consist of 8 cohorts receiving doses from 2 nanograms (2 ng) to 4000ng or a&#xD;
      placebo dose. Administration within each cohort will be staggered so that two subjects (one&#xD;
      receiving drug and one placebo) will be dosed and monitored for 24 hours before any&#xD;
      subsequent doses.&#xD;
&#xD;
      Screening for part 2 of the study will begin once data from cohort 4 in part 1 has been found&#xD;
      to be satisfactory. Part 2 will involve subjects with Allergic Rhinitis and be divided into&#xD;
      three cohorts receiving doses between 20ng and 4000ng or a placebo dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2011</start_date>
  <completion_date type="Actual">September 30, 2011</completion_date>
  <primary_completion_date type="Actual">September 30, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>From screening until follow-up</time_frame>
    <description>General safety endpoints, including AEs, vital signs, 12-lead ECG, body temperature and clinical laboratory safety tests to evaluate the safety and nasal tolerability of single escalation doses of GSK2245035 in healthy volunteers and individuals with Allergic Rhinitis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal Tolerability</measure>
    <time_frame>From screening until follow-up</time_frame>
    <description>Nasal examination and nasal symptom to assess nasal tolerability of single escalating doses of GSK2245035 in subjects with Allergic Rhinitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TLR7-associated Biomarkers</measure>
    <time_frame>From pre-dose until 3 days post-dose</time_frame>
    <description>Evaluation of the induction of TLR7-induced blood biomarkers in the nasal lavage and nasal tissues of individuals with AR following single GSK2245035 administration versus placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic PK</measure>
    <time_frame>From pre-dose until 3 days post-dose</time_frame>
    <description>Standard single dose derived plasma PK parameters for GSK2245035 in healthy volunteers and individuals with Allergic Rhinitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Evaluation</measure>
    <time_frame>From pre-dose until 3 days post-dose</time_frame>
    <description>To evaluate the correlation between GSK2245035 dose - systemic PK - PD blood biomarkers - PD nasal biomarkers in healthy volunteer and subjects with Allergic Rhinitis.</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1 GSK2445053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2ng GSK2245053</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2 GSK2445053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20ng GSK2445053</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 3 GSK2245053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100ng GSK2445053</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 4 GSK2445053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200ng GSK2445053</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 4 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 5 GSK245053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400ng GSK2445053</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 5 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 6 GSK2445053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000ng GSK2245053</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 6 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 7 GSK2445053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000ng GSK2445053</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 7 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 8 GSK2445053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4000ng GSK2445053</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 8 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 ng GSK2445053</intervention_name>
    <description>2ng GSK2445053 administered intranasally</description>
    <arm_group_label>Part 1 Cohort 1 GSK2445053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20ng GSK2445053</intervention_name>
    <description>20ng GSK2445053 administered intranasally</description>
    <arm_group_label>Part 1 Cohort 2 GSK2445053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100ng GSK2445053</intervention_name>
    <description>100ng GSK2445053 administered intranasally</description>
    <arm_group_label>Part 1 Cohort 3 GSK2245053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200ng GSK2445053</intervention_name>
    <description>200ng GSK2445053 administered intranasally</description>
    <arm_group_label>Part 1 Cohort 4 GSK2445053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400ng GSK2445053</intervention_name>
    <description>400ng GSK2445053 administered intranasally</description>
    <arm_group_label>Part 1 Cohort 5 GSK245053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000ng GSK2445053</intervention_name>
    <description>1000ng GSK2445053 administered intranasally</description>
    <arm_group_label>Part 1 Cohort 6 GSK2445053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2000ng GSK2445053</intervention_name>
    <description>2000ng GSK2445053 administered intranasally</description>
    <arm_group_label>Part 1 Cohort 7 GSK2445053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4000ng GSK2445053</intervention_name>
    <description>4000ng GSK2445053 administered intranasally</description>
    <arm_group_label>Part 1 Cohort 8 GSK2445053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered intranasally</description>
    <arm_group_label>Part 1 Cohort 1 Placebo</arm_group_label>
    <arm_group_label>Part 1 Cohort 2 Placebo</arm_group_label>
    <arm_group_label>Part 1 Cohort 3 Placebo</arm_group_label>
    <arm_group_label>Part 1 Cohort 4 Placebo</arm_group_label>
    <arm_group_label>Part 1 Cohort 5 Placebo</arm_group_label>
    <arm_group_label>Part 1 Cohort 6 Placebo</arm_group_label>
    <arm_group_label>Part 1 Cohort 7 Placebo</arm_group_label>
    <arm_group_label>Part 1 Cohort 8 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all subjects (parts 1 and 2)&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history,physical examination, laboratory testsand cardiac&#xD;
             monitoring. A subject with a clinical abnormality or laboratoryparameters outside the&#xD;
             reference range for the population being studied may be included only if the&#xD;
             Investigator agrees that the finding is unlikely to introduce additional risk factors&#xD;
             and will not interfere with the study procedures.&#xD;
&#xD;
          -  Male between 18 and 55 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the contraception methods listed in Section 8.1 of the protocol. This criterion must&#xD;
             be followed from the time of the first dose of study medication until one week&#xD;
             post-dosing.&#xD;
&#xD;
          -  Body weight greater than or equal to 50 kilograms (kg) and Body Mass Index (BMI)&#xD;
             within the range 19 - 29.9 kilograms per square metre (kg/m2) inclusive.&#xD;
&#xD;
          -  12 lead Electrocardiogram without any clinically significant abnormality as judged by&#xD;
             the Investigator, and average QT interval (QTc), QT interval corrected for Basett&#xD;
             (QTcB) or QT interval corrected for Fredericia (QTcF) less than 450 milliseconds&#xD;
&#xD;
          -  Aspartate transaminase (AST), alanine transamine (ALT), alkaline phosphatase and&#xD;
             bilirubin less than 1.5 x Upper Limit of Normal (ULN) (isolated bilirubin greater&#xD;
             than1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin less&#xD;
             than 35%).&#xD;
&#xD;
          -  Subjects have a screening pre-challenge Forced Expiratory Volume in 1 second (FEV1)&#xD;
             greater than or equal to 80% and a baseline FEV1/FVC greater than or equal to 70% of&#xD;
             the predicted value.&#xD;
&#xD;
          -  Subjects should refrain from smoking between screening and the end of the study, and&#xD;
             have a negative test for cotinine/ carbon monoxide (CO) at pre-dose.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Available to complete all the required study measurements.&#xD;
&#xD;
        Inclusion Criteria for Allergic Rhinitics only (Part 2)&#xD;
&#xD;
          -  History and diagnosis of symptomatic seasonal allergic rhinitis to pollen, for more&#xD;
             than 3 years.&#xD;
&#xD;
          -  Positive skin allergy test (wheal greater than or equal to 4miliimetres) or&#xD;
             radioallergosorbent test (RAST) greater than or equal to Class 2, for pollen&#xD;
             allergens.&#xD;
&#xD;
          -  Subjects have a Total Nasal Symptom Score (TNSS) score of greater than or equal to 3&#xD;
             during the current pollen season (Total nasal symptom score is the sum of nasal&#xD;
             congestion, rhinorrhoea, nasal itch and sneeze, each of which are scored on a scale&#xD;
             from 0 to 3).&#xD;
&#xD;
        Exclusion Criteria for all subjects (Parts 1 and 2):&#xD;
&#xD;
          -  History of immunologic or haematologic deficiencies or diseases, except conditions&#xD;
             that in the opinion of the Investigator and the GSK Medical Monitor are unlikely to&#xD;
             introduce additional risk factors.&#xD;
&#xD;
          -  Current diagnosis of asthma.&#xD;
&#xD;
          -  Nasal conditions likely to affect the outcome of the study, i.e. nasal septal&#xD;
             perforation, nasal polyps, other nasal malformations or history of frequent&#xD;
             nosebleeds.&#xD;
&#xD;
          -  History of haematologic, gastro-intestinal, hepatic, renal or other condition that may&#xD;
             influence the absorption, distribution, metabolism, excretion or action of the drug.&#xD;
&#xD;
          -  History of frequent headaches and/or migraine.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
          -  A positive test for Human Immunodeficiency Virus antibody&#xD;
&#xD;
          -  A positive screening or pre-dose drug/alcohol screen, or a positive pre-dose smoking&#xD;
             test&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: an&#xD;
             average weekly intake of greater than 21 units for males or greater than 14 units for&#xD;
             females. One unit is equivalent to 8 grams (8g) of alcohol: a half-pint or&#xD;
             approximately 240 millilitres (240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL)&#xD;
             measure of spirits.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within 3 months prior to the first dosing day in the current study.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 6 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  History of drug or other allergy that, in the opinion of the Investigator or GSK&#xD;
             Medical Monitor, contraindicates participation in this study.&#xD;
&#xD;
          -  Donation of blood or blood products in excess of 500 mL within a 90-day period.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated&#xD;
&#xD;
        Exclusion Criteria for healthy volunteers only (part 1)&#xD;
&#xD;
          -  History of rhinitis, including allergic, non-allergic rhinitis and rhinosinusitis.&#xD;
             Subjects with recent upper respiratory tract infections (URTIs) will be allowed in the&#xD;
             study only if their nasal symptoms have been completely resolved for more than 3 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to entry to the&#xD;
             clinic, unless in the opinion of the Investigator and GSK Medical Monitor the&#xD;
             medication will not interfere with the study procedures or compromise subject safety.&#xD;
&#xD;
        Exclusion criteria for Allergic Rhinitics only (part 2)&#xD;
&#xD;
          -  Subjects with recent upper respiratory tract infections (URTIs) will be allowed in the&#xD;
             study only if their nasal symptoms have been completely resolved for more than 3 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to entry into&#xD;
             the clinic, unless in the opinion of the Investigator and GSK Medical Monitor the&#xD;
             medication will not interfere with the study procedures or compromise subject safety.&#xD;
             Subjects using treatment for allergies and AR may participate in the study if they&#xD;
             remain free of medication for the following periods of time prior to entry into the&#xD;
             clinic:&#xD;
&#xD;
               -  Nasal antihistamines: 48 hours&#xD;
&#xD;
               -  Oral antihistamines A (cetirizine, fexofenadine, loratadine, desloratadine): 72&#xD;
                  hours&#xD;
&#xD;
               -  Oral antihistamines B (all others): 72 hours&#xD;
&#xD;
               -  Nasal decongestants: 24 hours&#xD;
&#xD;
               -  Oral decongestants: 24 hours&#xD;
&#xD;
               -  Nasal glucocorticosteroids: 4 weeks&#xD;
&#xD;
               -  Oral glucocorticosteroids: 12 weeks&#xD;
&#xD;
               -  Oral leukotriene receptor antagonists: 7 days&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2011</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Single Dose Escalation</keyword>
  <keyword>TLR7 agonist</keyword>
  <keyword>First Time in Human Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114450</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114450</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114450</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114450</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114450</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114450</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114450</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

